Recent advancements of flow cytometry: new applications in hematology and oncology

References

• Fulwyler MJ. Electronic separation of biological cells by volume. Science 150(3698), 910–911 (1965).
   PubMedGoogle Scholar
• Ho LL, Sinha A, Verzi M, Bernt KM, Armstrong SA, Shivdasani RA. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. Mol. Cell Biol. 33(9), 1735–1745 (2013).
   PubMedGoogle Scholar
• Kalina T, Flores-Montero J, van der Velden VH et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26(9), 1986–2010 (2012).
   PubMed Web of Science ®Google Scholar
• Duque RE, Andreeff M, Braylan RC, Diamond LW, Peiper SC. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry 14(5), 492–496 (1993).
   PubMedGoogle Scholar
• Peters JM, Ansari MQ. Multiparameter flow cytometry in the diagnosis and management of acute leukemia. Arch. Pathol. Lab Med. 135(1), 44–54 (2011).
   PubMed Web of Science ®Google Scholar
• Paietta E, Goloubeva O, Neuberg D et al. A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. Cytometry B Clin. Cytom. 59(1), 1–9 (2004).
   PubMedGoogle Scholar
• Khoury H, Dalal BI, Nevill TJ et al. Acute myelogenous leukemia with t(8;21)-identification of a specific immunophenotype. Leuk. Lymphoma 44(10), 1713–1718 (2003).
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N. Engl. J. Med. 352(3), 254–266 (2005).
   PubMed Web of Science ®Google Scholar
• Haferlach C, Mecucci C, Schnittger S et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood 114(14), 3024–3032 (2009).
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Mullighan CG, Onciu M et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 10(2), 147–156 (2009).
   PubMed Web of Science ®Google Scholar
• Vitale A, Guarini A, Ariola C et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 107(2), 473–479 (2006).
   PubMed Web of Science ®Google Scholar
• Uckun FM, Gaynon PS, Sensel MG et al. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children’s Cancer Group study. J. Clin. Oncol. 15(6), 2214–2221 (1997).
   PubMed Web of Science ®Google Scholar
• Niehues T, Kapaun P, Harms DO et al. A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Leukemia 13(4), 614–617 (1999).
   PubMed Web of Science ®Google Scholar
• Brown M, Wittwer C. Flow cytometry: principles and clinical applications in hematology. Clin. Chem. 46(8 Pt 2), 1221–1229 (2000).
   PubMedGoogle Scholar
• Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am. J. Clin. Pathol. 121(4), 482–488 (2004).
   PubMed Web of Science ®Google Scholar
• Kussick SJ, Fromm JR, Rossini A et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am. J. Clin. Pathol. 124(2), 170–181 (2005).
   PubMedGoogle Scholar
• Malcovati L, Della Porta MG, Lunghi M et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 19(5), 776–783 (2005).
   PubMed Web of Science ®Google Scholar
• Hamblin TJ. Searching for surrogates for IGHV mutations in chronic lymphocytic leukemia. Leuk. Res. 35(11), 1432–1435 (2011).
   PubMedGoogle Scholar
• Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348(18), 1764–1775 (2003).
   PubMed Web of Science ®Google Scholar
• Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 86(11), 928–948 (2011).
   PubMed Web of Science ®Google Scholar
• Pettitt AR, Jackson R, Carruthers S et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J. Clin. Oncol. 30(14), 1647–1655 (2012).
   PubMed Web of Science ®Google Scholar
• Irish JM, Hovland R, Krutzik PO et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118(2), 217–228 (2004).
   PubMed Web of Science ®Google Scholar
• Irish JM, Anensen N, Hovland R et al. Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood 109(6), 2589–2596 (2007).
   PubMed Web of Science ®Google Scholar
• Irish JM, Czerwinski DK, Nolan GP, Levy R. Kinetics of B cell receptor signaling in human B cell subsets mapped by phospho-specific flow cytometry. J. Immunol. 177(3), 1581–1589 (2006).
   PubMed Web of Science ®Google Scholar
• Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program 2010, 7–12 (2010).
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen JL. Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time? J. Natl Compr. Canc. Netw. 10(8), 1029–1036 (2012).
   PubMedGoogle Scholar
• Lodewyck T, Cornelissen JJ. Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach. Blood Rev. 22(6), 293–302 (2008).
   PubMedGoogle Scholar
• Buccisano F, Maurillo L, Del Principe MI et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 119(2), 332–341 (2012).
   PubMed Web of Science ®Google Scholar
• Kern W, Bacher U, Haferlach C, Schnittger S, Haferlach T. The role of multiparameter flow cytometry for disease monitoring in AML. Best Pract. Res. Clin. Haematol. 23(3), 379–390 (2010).
   PubMed Web of Science ®Google Scholar
• Grimwade D, Vyas P, Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr. Opin. Oncol. 22(6), 656–663 (2010).
   PubMed Web of Science ®Google Scholar
• Campana D. Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia. Hematol. Oncol. Clin. North Am. 23(5), 1083–1098, vii (2009).
   PubMed Web of Science ®Google Scholar
• Coustan-Smith E, Sandlund JT, Perkins SL et al. Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children’s oncology group. J. Clin. Oncol. 27(21), 3533–3539 (2009).
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Devidas M, Hunger SP et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children’s Oncology Group study. Blood 111(12), 5477–5485 (2008).
   PubMed Web of Science ®Google Scholar
• Baer MR, Stewart CC, Dodge RK et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 97(11), 3574–3580 (2001).
   PubMedGoogle Scholar
• Arnoulet C, Bene MC, Durrieu F et al. Four- and five-color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: a reference document based on a systematic approach by the GTLLF and GEIL. Cytometry B Clin. Cytom. 78(1), 4–10 (2010).
   PubMedGoogle Scholar
• Rawstron AC, Child JA, de Tute RM et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the medical research council myeloma IX study. J. Clin. Oncol. 31(20), 2540–2547 (2013).
   PubMed Web of Science ®Google Scholar
• Bottcher S, Ritgen M, Fischer K et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J. Clin. Oncol. 30(9), 980–988 (2012).
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Villamor N, Ritgen M et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21(5), 956–964 (2007).
   PubMed Web of Science ®Google Scholar
• Campana D. Molecular determinants of treatment response in acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program 366–373 (2008).
   Google Scholar
• Coustan-Smith E, Ribeiro RC, Stow P et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood 108(1), 97–102 (2006).
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Krawczyk-Kulis M, Giebel S et al. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br. J. Haematol. 142(2), 227–237 (2008).
   PubMed Web of Science ®Google Scholar
• Elorza I, Palacio C, Dapena JL, Gallur L, Sanchez de Toledo J, Diaz de Heredia C. Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia. Haematologica 95(6), 936–941 (2010).
   PubMed Web of Science ®Google Scholar
• Sanchez J, Serrano J, Gomez P et al. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br. J. Haematol. 116(3), 686–694 (2002).
   PubMedGoogle Scholar
• Sanchez-Garcia J, Serrano J, Serrano-Lopez J et al. Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL. Bone Marrow Transplant. 48(3), 396–402 (2013).
   PubMed Web of Science ®Google Scholar
• Venditti A, Buccisano F, Del Poeta G et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96(12), 3948–3952 (2000).
   PubMed Web of Science ®Google Scholar
• Venditti A, Maurillo L, Buccisano F et al. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia 17(11), 2178–2182 (2003).
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Gattei V et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia 20(10), 1783–1789 (2006).
   PubMed Web of Science ®Google Scholar
• Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 104(10), 3078–3085 (2004).
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, Wood BL et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J. Clin. Oncol. 29(9), 1190–1197 (2011).
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Dahl G et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 11(6), 543–552 (2010).
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Crews KR, Pounds S et al. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia 23(8), 1410–1416 (2009).
   PubMed Web of Science ®Google Scholar
• Lange BJ, Smith FO, Feusner J et al. Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children’s oncology group. Blood 111(3), 1044–1053 (2008).
   PubMed Web of Science ®Google Scholar
• Becton D, Dahl GV, Ravindranath Y et al. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 107(4), 1315–1324 (2006).
   PubMedGoogle Scholar
• Coustan-Smith E, Campana D. Should evaluation for minimal residual disease be routine in acute myeloid leukemia? Curr. Opin. Hematol. 20(2), 86–92 (2013).
   PubMed Web of Science ®Google Scholar
• Bottcher S, Ritgen M, Kneba M. Flow cytometric MRD detection in selected mature B-cell malignancies. Methods Mol. Biol. 971, 149–174 (2013).
   PubMedGoogle Scholar
• Tuchin VV, Tarnok A, Zharov VP. In vivo flow cytometry: a horizon of opportunities. Cytometry A 79(10), 737–745 (2011).
   PubMed Web of Science ®Google Scholar
• Tkaczyk ER, Tkaczyk AH. Multiphoton flow cytometry strategies and applications. Cytometry A 79(10), 775–788 (2011).
   PubMedGoogle Scholar
• Benaron DA. The future of cancer imaging. Cancer Metastasis Rev. 21(1), 45–78 (2002).
   PubMed Web of Science ®Google Scholar
• He W, Wang H, Hartmann LC, Cheng JX, Low PS. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc. Natl Acad. Sci. USA 104(28), 11760–11765 (2007).
   PubMed Web of Science ®Google Scholar
• Galanzha EI, Shashkov EV, Kelly T, Kim JW, Yang L, Zharov VP. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat. Nanotechnol. 4(12), 855–860 (2009).
   PubMed Web of Science ®Google Scholar
• Galanzha EI, Kokoska MS, Shashkov EV, Kim JW, Tuchin VV, Zharov VP. In vivo fiber-based multicolor photoacoustic detection and photothermal purging of metastasis in sentinel lymph nodes targeted by nanoparticles. J. Biophotonics 2(8–9), 528–539 (2009).
   PubMedGoogle Scholar
• Galanzha EI, Shashkov EV, Spring PM, Suen JY, Zharov VP. In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res. 69(20), 7926–7934 (2009).
   PubMed Web of Science ®Google Scholar
• Nedosekin DA, Sarimollaoglu M, Ye JH, Galanzha EI, Zharov VP. In vivo ultra-fast photoacoustic flow cytometry of circulating human melanoma cells using near-infrared high-pulse rate lasers. Cytometry A 79(10), 825–833 (2011).
   PubMedGoogle Scholar
• Chang YC, Ye JY, Thomas TP et al. Fiber-optic multiphoton flow cytometry in whole blood and in vivo. J. Biomed. Opt. 15(4), 047004 (2010).
   Google Scholar
• Galanzha EI, Sarimollaoglu M, Nedosekin DA, Keyrouz SG, Mehta JL, Zharov VP. In vivo flow cytometry of circulating clots using negative photothermal and photoacoustic contrasts. Cytometry A 79(10), 814–824 (2011).
   PubMedGoogle Scholar
• Galanzha EI, Shashkov E, Sarimollaoglu M et al. In vivo magnetic enrichment, photoacoustic diagnosis, and photothermal purging of infected blood using multifunctional gold and magnetic nanoparticles. PLoS ONE 7(9), e45557 (2012).
   PubMed Web of Science ®Google Scholar
• Galanzha EI, Zharov VP. Photoacoustic flow cytometry. Methods 57(3), 280–296 (2012).
   PubMedGoogle Scholar
• Nedosekin DA, Juratli MA, Sarimollaoglu M et al. Photoacoustic and photothermal detection of circulating tumor cells, bacteria and nanoparticles in cerebrospinal fluid in vivo and ex vivo. J. Biophotonics 6(6–7), 523–533 (2013).
   PubMedGoogle Scholar
• Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK. A deep profiler’s guide to cytometry. Trends Immunol. 33(7), 323–332 (2012).
   PubMed Web of Science ®Google Scholar
• Bandura DR, Baranov VI, Ornatsky OI et al. Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. Anal. Chem. 81(16), 6813–6822 (2009).
   PubMed Web of Science ®Google Scholar
• Chattopadhyay PK. Quantum dot technology in flow cytometry. Methods Cell Biol. 102, 463–477 (2011).
   PubMed Web of Science ®Google Scholar
• Majonis D, Herrera I, Ornatsky O et al. Synthesis of a functional metal-chelating polymer and steps toward quantitative mass cytometry bioassays. Anal. Chem. 82(21), 8961–8969 (2010).
   PubMed Web of Science ®Google Scholar